Bloomberg L.P.2h
GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
STAT8m
Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
BioPharma Dive16h
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a ...
Morningstar22h
AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia Study Setback
AbbVie in September said another Cerevel drug candidate, tavapadon, met the primary endpoint in a pivotal Phase 3 study in the neurodegenerative disorder Parkinson's disease. AbbVie shares, which hit ...